Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Assessment of Pomaglumetad in Healthy Volunteers
NCT02919774Phase 1Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pomaglumetad methionil in schizophrenia (3 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: PharmacoBOLD change at Day 10. Started Oct 2016; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02919774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919774.